Department of Ophthalmology, Edith Crawley Vision Research Center, University of Cincinnati, Cincinnati, OH, USA.
J Cell Mol Med. 2012 May;16(5):1114-24. doi: 10.1111/j.1582-4934.2011.01418.x.
It remains elusive as to what bone marrow (BM) cell types infiltrate into injured and/or diseased tissues and subsequently differentiate to assume the phenotype of residential cells, for example, neurons, cardiac myocytes, keratocytes, etc., to repair damaged tissue. Here, we examined the possibility of whether BM cell invasion via circulation into uninjured and injured corneas could assume a keratocyte phenotype, using chimeric mice generated by transplantation of enhanced green fluorescent protein (EGFP)(+) BM cells into keratocan null (Kera(-/-)) and lumican null (Lum(-/-)) mice. EGFP(+) BM cells assumed dendritic cell morphology, but failed to synthesize corneal-specific keratan sulfate proteoglycans, that is KS-lumican and KS-keratocan. In contrast, some EGFP(+) BM cells introduced by intrastromal transplantation assumed keratocyte phenotypes. Furthermore, BM cells were isolated from Kera-Cre/ZEG mice, a double transgenic mouse line in which cells expressing keratocan become EGFP(+) due to the synthesis of Cre driven by keratocan promoter. Three days after corneal and conjunctival transplantations of such BM cells into Kera(-/-) mice, green keratocan positive cells were found in the cornea, but not in conjunctiva. It is worthy to note that transplanted BM cells were rejected in 4 weeks. MSC isolated from BM were used to examine if BM mesenchymal stem cells (BM-MSC) could assume keratocyte phenotype. When BM-MSC were intrastromal-transplanted into Kera(-/-) mice, they survived in the cornea without any immune and inflammatory responses and expressed keratocan in Kera(-/-) mice. These observations suggest that corneal intrastromal transplantation of BM-MSC may be an effective treatment regimen for corneal diseases involving dysfunction of keratocytes.
骨髓(BM)细胞类型如何浸润到受伤和/或患病组织中,随后分化为常驻细胞表型,例如神经元、心肌细胞、角质细胞等,以修复受损组织,其机制仍不清楚。在这里,我们通过将增强型绿色荧光蛋白(EGFP)(+)BM 细胞移植到角膜蛋白聚糖缺失(Kera(-/-))和 lumican 缺失(Lum(-/-))小鼠中,检查了 BM 细胞是否通过循环侵入未受伤和受伤的角膜以获得角膜细胞表型的可能性。EGFP(+)BM 细胞呈现树突状细胞形态,但未能合成角膜特异性硫酸角质素蛋白聚糖,即 KS-lumican 和 KS-keratocan。相比之下,一些通过基质内移植引入的 EGFP(+)BM 细胞获得了角膜细胞表型。此外,从 Kera-Cre/ZEG 小鼠中分离出 BM 细胞,这是一种双转基因小鼠系,由于角膜启动子驱动的 Cre 合成,表达角膜蛋白聚糖的细胞成为 EGFP(+)。将这种 BM 细胞角膜和结膜移植到 Kera(-/-)小鼠后 3 天,在角膜中发现了绿色角膜蛋白聚糖阳性细胞,但在结膜中没有。值得注意的是,移植的 BM 细胞在 4 周内被排斥。从 BM 分离的 MSC 用于检查 BM 间充质干细胞(BM-MSC)是否可以获得角膜细胞表型。当 BM-MSC 被基质内移植到 Kera(-/-)小鼠中时,它们在角膜中存活而没有任何免疫和炎症反应,并在 Kera(-/-)小鼠中表达角膜蛋白聚糖。这些观察结果表明,BM-MSC 的角膜基质内移植可能是治疗涉及角膜细胞功能障碍的角膜疾病的有效治疗方案。